MRVL Stock Recent News

Marvell Technology (MRVL) reachead $51.70 at the closing of the latest trading day, reflecting a -0.44% change compared to its last close.

The semiconductor sector is bracing for a shakeup, and JPMorgan's Harlan Sur isn't mincing words. "Expect in-line results but tariff/trade related dynamics to drive weaker 2Q/2H25 and negative earnings revision cycle.

Live Updates Live Coverage Updates appear automatically as they are published. U.S. to Isolate China 12:53 pm U.S. authorities are preparing to engage in talks with over 70 countries, urging them to block Chinese goods from passing through their territories, according to the WSJ. The U.S. aims to economically “cut off” China. This aligns with President Trump’s recent statement suggesting nations might need to choose between aligning with the U.S. or China. The approach seems to focus on fully isolating China, while China has pledged to stand firm. Technology Stocks Upgrades and Downgrades 11:00 am MSFT (Microsoft) Downgrade Details: BMO Capital reduced price target from $490 to $470, maintains Outperform rating. Reason: Slower growth in Azure’s legacy cloud business due to weaker economy, leading to reduced Azure growth estimates for next few quarters and FY26. Insight: Experts indicate slowdown in core legacy cloud businesses. BMO suggests lower capex intensity

Marvell (MRVL) possesses solid growth attributes, which could help it handily outperform the market.

The ongoing U.S.-China trade tensions, particularly around chip tariffs, are causing significant volatility and anxiety for tech investors, impacting stocks like Nvidia, AMD, and Marvell. Despite the tariff issues, AI growth remains strong, and high-quality chip companies could remain highly profitable, with the potential for a trade deal boosting their stocks. Nvidia, AMD, and Marvell have seen substantial stock price declines, making them relatively cheap with strong future profitability prospects despite temporary earnings declines.

Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France.

Tech is one of the best places to look for bargain-priced stocks now, because the sector has been hit so hard. The worst of the tariff storm could be behind us.

Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conference (AAIC), taking place in July 2025. The Company will present preclinical data from its acute Alzheimer's disease study, conducted in collaboration with Professor Emmanuel Planel, a global expert in tau pathology.

Today's Chart Master segment turns to three stocks seeing new analyst reaction as they trade well-below their all-time highs. Jenny Horne talks about Citi's price target cut on Marvell (MRVL), Piper Sandler's halved price target on Deckers (DECK), and Mizuho initiating coverage on Target (TGT) with a neutral rating.

Shares of Marvell Technology Inc. NASDAQ: MRVL spiked over 10% higher on April 9 after the Trump administration announced a 90-day pause on reciprocal tariffs. Additionally, the company announced it had sold its Automotive Ethernet business to Infineon Technologies AG OTC: IFNNY for $2.5 billion.